Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology

2019 ◽  
Vol 21 (5) ◽  
Author(s):  
Blandine Rammaert ◽  
Mathieu Puyade ◽  
Oliver A. Cornely ◽  
Danila Seidel ◽  
Paolo Grossi ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Fungal Infection ◽  
Medical Mycology ◽  
Study Group ◽  
Practice Survey ◽  
Infection Study ◽  
Scedosporium Species

Micafungin Is Extremely Effective Against Fungal Infections Complicating Hematological Malignancies: Report of a Multicenter Study by N-FISH (Niigata Fungal Infection Study Group in Hematology).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5350-5350
Author(s):  
Sadao Aoki ◽  
Jun Takizawa ◽  
Yoshinobu Seki ◽  
Kazue Takai ◽  
Koji Nikkuni ◽  
...  
Keyword(s):  
Adverse Events ◽  
Fungal Infection ◽  
Multicenter Study ◽  
Liver Dysfunction ◽  
Hematological Malignancies ◽  
Fungal Infections ◽  
The United States ◽  
Study Group ◽  
The Mean ◽  
Infection Study

Abstract [Background]Micafungin (MCFG) is a candin antifungal agent, and was marketed in Dec. 2002 in Japan and in Apr. 2005 in the United States. The Niigata Fungal Infection Study Group in Hematology (N-FISH) performed a multicenter prospective study to clarify the therapeutic effects of MCFG on deep fungal infections complicating hematological malignancies. [Methods]A total of 36 pts. who had been treated in centers belonging to N-FISH between Oct. 2003 and Apr. 2005 were included in this study. They consisted of 14 men and 22 women with a mean age of 53.5 years: 14 pts. with AML, 10 pts. with malignant lymphoma, 6 pts. with ALL, and 6 pts with other diseases. They had a proven fungal infection, or were suspected of having a fungal infection because of fever unresponsive to antimicrobial agents or from laboratory data. Three of them had a proven infection, and 33 were suspected of having a fungal infection. Three of these 33 pts. failed to respond to fluconazole. As a rule, MCFG was administered for more than 14 days until infectious symptoms improved or disappeared. When MCFG was judged ineffective because of the worsening of clinical symptoms despite the administration of MCFG, or when the administration of MCFG was judged difficult because of adverse effects, the drug was discontinued or replaced by other drugs. Two pts. orally received amphotericin B syrup singly. [Results]The mean dose of MCFG was 2.6 mg/kg (1.5–4.2 mg/kg), and the mean duration of administration was 15.9 days (5–85 days). Complete or partial response was achieved in 31 (86.1%) of the 36 pts., who showed improvements in infectious symptoms. In 4 pts, MCFG was discontinued because of insufficient effects. There were no breakthrough fungal infections within 7 days after the completion of MCFG therapy. Of the 36 pts., 31 (86.1%) and 24 (66.7%) survived 1 and 3 months after MCFG therapy, respectively. The cause of death was exacerbation of the primary disease, and not exacerbation or the onset of a fungal infection. Eight adverse events occurred in 7 pts.: hypoglycemia in 1, liver dysfunction in 3, eosinophilia in 1, kidney dysfunction in 2, and hypokalemia in 1. In 1 of the 3 pts. with liver dysfunction (grade 3), MCFG therapy was discontinued, with rapid improvement of the liver dysfunction. All other adverse events were mild, allowing continued MCFG therapy. [Conclusion]This multicenter study demonstrated the effectiveness and safety of MCFG therapy for deep fungal infections complicating hematological malignancies. The results suggest that MCFG should be promptly used for fever associated with a fungal infection complicating hematological malignancies.

scholarly journals Risk and outcomes of pulmonary fungal infection after pediatric lung transplantation

2017 ◽  
Vol 31 (11) ◽  
pp. e13100 ◽  
Author(s):  
Evan Ammerman ◽  
Stuart C. Sweet ◽  
Matthew Fenchel ◽  
Gregory A. Storch ◽  
Carol Conrad ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Fungal Infection

Necrotizing Choroiditis-Retinitis as Presenting Symptom of Disseminated Aspergillosis after Lung Transplantation

1997 ◽  
Vol 7 (3) ◽  
pp. 294-296 ◽  
Author(s):  
I. Anteby ◽  
M. Kramer ◽  
G. Rahav ◽  
D. Benezra
Keyword(s):  
Lung Transplantation ◽  
Fungal Infection ◽  
Aspergillus Fumigatus ◽  
Endogenous Endophthalmitis ◽  
Ocular Involvement ◽  
Blurred Vision ◽  
Systemic Manifestations ◽  
Lung Transplants ◽  
Disseminated Aspergillosis ◽  
Aspergillus Endophthalmitis

Background. Endogenous endophthalmitis due to Aspergillus is rare affecting the severely immunosuppressed population, in particular recipients of heart and lung transplants. Ocular involvement of aspergillosis has always been observed late in the course of the disease. Subject. A young woman noted blurred vision in one eye three weeks after lung transplantation. At this stage, no systemic manifestations of fungal infection were detected and the ocular findings were attributed to viral infection. Results. Twenty-four hours after the original ocular complaint, an aggressive endophthalmitis developed in the left eye. The possibility of fungal endophthalmitis was raised. Within 48 hours of her first ocular complaint the patient died. Cultures from a vitreous tap and from autopsy ocular specimens were positive for Aspergillus fumigatus. Conclusions. Aspergillus endophthalmitis may occur in patients undergoing lung transplantation despite antifungal therapy. Increased awareness of this unusual entity may be life and vision saving in these patients.

Sign in / Sign up

Export Citation Format

Share Document